Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress

Retrieved on: 
Tuesday, October 29, 2019
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Companies, CAC 40, Sanofi, Life sciences, Economy of France, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Follicular Lymphoma, Peripheral T-Cell Lymphoma, COPIKTRA™ (duvelisib), Verastem Oncology

License and collaboration revenue for the 2019 Quarter was $5.0 million, compared to $15.0 million for the 2018 Quarter.

Key Points: 
  • License and collaboration revenue for the 2019 Quarter was $5.0 million, compared to $15.0 million for the 2018 Quarter.
  • The 2019 Quarter includes a $5.0 million upfront payment received pursuant to a license and collaboration agreement executed between Verastem Oncology and Sanofi in July 2019.
  • Total operating expenses for the 2019 Quarter were $35.1 million, compared to $41.4 million for the second quarter of 2019 and compared to $37.1 million for the 2018 Quarter.
  • Research and development (R&D) expense for the 2019 Quarter was $12.2 million, compared to $11.6 million for the 2018 Quarter.

Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting

Retrieved on: 
Tuesday, September 3, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, HIV/AIDS, Pneumonia, Pneumocystis pneumonia, Organ systems, PJP, Pneumocystis jirovecii, Marginal zone B-cell lymphoma, Medical specialties, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, COPIKTRA™ (duvelisib), Verastem Oncology

The fourth poster describes efficacy and safety data from the Phase 2 DYNAMO evaluating COPIKTRA patients with refractory marginal zone lymphoma (MZL).

Key Points: 
  • The fourth poster describes efficacy and safety data from the Phase 2 DYNAMO evaluating COPIKTRA patients with refractory marginal zone lymphoma (MZL).
  • Continued approval in FL may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Cases of Pneumocystis jirovecii pneumonia (PJP) (1%) and cytomegalovirus (CMV) reactivation/infection (1%) occurred in patients taking COPIKTRA.
  • Hepatotoxicity: Grade 3 and 4 ALT and/or AST elevation developed in 8% and 2%, respectively, of patients receiving COPIKTRA (N=442).

Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, August 1, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Oi, Companies, Industry in Brazil, Economy of Brazil, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Follicular Lymphoma, Peripheral T-Cell Lymphoma, COPIKTRA™ (duvelisib), Verastem Oncology

Key Second Quarter 2019 and Recent Accomplishments:

Key Points: 
  • Key Second Quarter 2019 and Recent Accomplishments:
    Brian Stuglik Appointed Chief Executive Officer and Other Leadership Changes In July, Verastem Oncology announced the appointment of Brian Stuglik as Chief Executive Officer.
  • Net product revenue for the three months ended June 30, 2019 (2019 Quarter) was $3.0 million, which reflects the third full quarter of recorded sales for COPIKTRA.
  • License and collaboration revenue for the 2019 Quarter was $0.1 million, compared to $10.0 million for the 2018 Quarter.
  • Research and development (R&D) expense for the 2019 Quarter was $11.3 million, compared to $12.4 million for the 2018 Quarter.

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma

Retrieved on: 
Friday, June 21, 2019
Oncology, Health, General Health, Pharmaceutical, Biotechnology, Antineoplastic drugs, Duvelisib, Oncology, Draft:Verastem Oncology, COPIKTRA™ (duvelisib), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Peripheral T-Cell Lymphoma, Verastem Oncology

Although the patient numbers are small in these two Phase 1 studies, we see a positive trend in response rates.

Key Points: 
  • Although the patient numbers are small in these two Phase 1 studies, we see a positive trend in response rates.
  • The preliminary safety profile of duvelisib in patients with relapsed or refractory PTCL was considered reasonable and consistent with prior studies.
  • Infections: Serious, including fatal (18/442; 4%), infections occurred in 31% of patients receiving COPIKTRA 25 mg BID (N=442).
  • Cutaneous Reactions: Serious, including fatal (2/442;